Dual antiplatelet therapy in the secondary prevention of atherothrombosis: need for new therapeutic approaches.
INSERM U765, University Paris Descartes, Paris, France.
Brigitte
B
Sabatier
Ludovic
L
Trinquart
Joseph
J
Emmerich
D050197:Atherosclerosis / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D055502:Secondary Prevention; D013927:Thrombosis / Q000517:prevention & control*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors